Canada markets close in 3 hours 42 minutes
  • S&P/TSX

    +216.08 (+1.00%)
  • S&P 500

    +16.92 (+0.31%)
  • DOW

    +364.20 (+0.93%)

    +0.0019 (+0.26%)

    +0.79 (+0.98%)
  • Bitcoin CAD

    -4,393.20 (-5.02%)
  • CMC Crypto 200

    -56.00 (-4.28%)

    +10.00 (+0.43%)
  • RUSSELL 2000

    +16.43 (+0.81%)
  • 10-Yr Bond

    +0.0120 (+0.28%)

    -47.14 (-0.27%)

    -0.04 (-0.30%)
  • FTSE

    +43.83 (+0.53%)
  • NIKKEI 225

    +208.18 (+0.54%)

    -0.0004 (-0.06%)

QIAGEN receives approval for its net-zero carbon emissions target by Science Based Targets initiative (SBTi)

SBTi has validated the QIAGEN targets to reach net-zero greenhouse gas (GHG) emissions

Venlo, The Netherlands, March 27, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its emissions reduction targets have been validated by the Science Based Targets initiative (SBTi) – a global recognition of its ambitions to honor the Paris Agreement’s climate goals.

The SBTi is a global body that enables companies to set ambitious emissions reductions targets in line with the latest climate science. Its Net-Zero Standard is the world’s first science-based certification of the net-zero targets set by companies around the world in line with the Paris Agreement's goal of keeping planetary warming to 1.5°C.

This validation makes QIAGEN one of only a few companies in the pharmaceuticals, life sciences and biotechnology sector with a verified net-zero science-based target. QIAGEN has pledged to hit net-zero greenhouse gas (GHG) emissions by 2050 from 2020 as the base year.


“QIAGEN welcomes the chance to join the group of companies in the world with a verified net-zero target based on science. We believe that it is our moral and strategic responsibility to invest in sustainable business practices. Our stakeholders, including our employees and customers, rightfully expect this from us. We are doing this to help safeguard the environment, but also to ensure the long-term viability of our activities,” said Thierry Bernard, CEO of QIAGEN. “We still have a long way to go at QIAGEN in reaching our goals, but we believe that every step is vital in the fight against climate change.”

QIAGEN has committed to reducing absolute GHG output from its direct and indirect operations (Scope 1 and 2 emissions) by 42% by 2030 from a 2020 base year – and the emissions from business travel as well as the use and end-of-life treatment of sold products (Scope 3) by 25% within the same timeframe. It has also pledged that 67% of its suppliers by emissions covering purchased goods and services, capital goods and upstream transportation and distribution will have targets in line with the SBTi by 2027.

These goals have been designed to put QIAGEN on a course to reduce its absolute Scope 1, 2 and 3 emissions by 90% by 2050 from 2020 as the base year.

QIAGEN is seeking to achieve net-zero status by cutting direct and indirect emissions throughout its operations. This goal is planned to be achieved through a series of measures – including transitioning facilities to renewable energy, implementing energy-saving initiatives, minimizing waste in manufacturing, reducing its total plastic footprint, and working with suppliers and logistical operators to reduce their carbon footprints. At the end of 2022, almost 80% of the company’s electricity came from renewable resources. Also in 2022, QIAGEN reduced its plastic usage by 16%, and exceeding the target for at least a 9% reduction.

Commitment to broad range of sustainability initiatives

QIAGEN has made visible progress in its efforts towards environmental topics, but also regarding its social and governance impact. One of QIAGEN’s key ESG goals is to improve global access to healthcare. For example, the company has expanded screening for tuberculosis and made more than 100 million QuantiFERON tests available in over 130 countries. QIAGEN has also enabled screening for human papillomavirus (HPV) in low-resource areas.

With regards to governance, QIAGEN is committed to conducting business lawfully, ethically, and with high integrity. QIAGEN has established a comprehensive Compliance Program that applies to all employees and third-party intermediaries, such as distributors or agents. QIAGEN also adheres to global procedures for clinical studies and requires its suppliers to commit to strict procurement standards.

For its sustainability efforts, QIAGEN was recognized by various rating agencies in 2022. These include a “Prime” status by ISS ESG, and an A-rating from MSCI ESG Research.

QIAGEN plans to regularly provide updates on the progress to reach net zero as part of its overall sustainability performance in its Annual and Sustainability Reports.

More information about QIAGEN’s commitment to climate protection and sustainability can be found here:



QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2022, QIAGEN employed approximately 6,200 people in over 35 locations worldwide. Further information can be found at

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Source: QIAGEN N.V.

Category: Corporate

CONTACT: John Gilardi QIAGEN N.V. +49 2103 29 11711 Phoebe Loh QIAGEN N.V. +49 2103 29 11457 Thomas Theuringer QIAGEN N.V. +49 2103 29 11826 Daniela Eltrop QIAGEN N.V. +49 2103 29 11676